Hepatitis A vaccine immunogenicity among seronegative liver transplanted children.

Autor: Sintusek P; Center of Excellence in Thai Pediatric Gastroenterology, Hepatology and Immunology (TPGHAI), Faculty of Medicine, Department of Pediatrics, King Chulalongkorn Memorial Hospital and Thai Red Cross Society, Chulalongkorn University, Bangkok, 10330, Thailand. palittiya.s@chula.ac.th., Khunsri S; Center of Excellence in Thai Pediatric Gastroenterology, Hepatology and Immunology (TPGHAI), Faculty of Medicine, Department of Pediatrics, King Chulalongkorn Memorial Hospital and Thai Red Cross Society, Chulalongkorn University, Bangkok, 10330, Thailand., Vichaiwattana P; Center of Excellence in Clinical Virology, Faculty of Medicine King Chulalongkorn Memorial Hospital and Thai Red Cross Society, Chulalongkorn University, Bangkok, 10330, Thailand., Polsawat W; Excellence Center for Organ Transplantation, King Chulalongkorn Memorial Hospital and Thai Red Cross Society, Chulalongkorn University, Bangkok, 10330, Thailand., Buranapraditkun S; Division of Allergy and Clinical Immunology, Department of Medicine, King Chulalongkorn Memorial Hospital and Thai Red Cross Society, Chulalongkorn University, Bangkok, 10330, Thailand., Poovorawan Y; Center of Excellence in Clinical Virology, Faculty of Medicine King Chulalongkorn Memorial Hospital and Thai Red Cross Society, Chulalongkorn University, Bangkok, 10330, Thailand. Yong.P@chula.ac.th.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Sep 27; Vol. 14 (1), pp. 22202. Date of Electronic Publication: 2024 Sep 27.
DOI: 10.1038/s41598-024-73390-z
Abstrakt: The hepatitis A virus (HAV) vaccine is highly immunogenic in general, yet data on its use in liver-transplanted (LT) children is limited. This study aimed to determine the seroimmunity to HAV in all LT children, and the immunogenicity of an inactivated HAV vaccine in seronegative LT children at King Chulalongkorn Memorial Hospital. Seronegative LT children received the inactivated HAV vaccine at 0 and 6-8 months with adverse events monitored for 3 days post-immunization. The result reviewed that among 105 LT children, vaccination records were available for 81%, of which 7.1% and 16.5% with one and two doses of HAV vaccine were immunized before transplantation, respectively. Post-transplantation, 20.1% were seropositive for HAV, with 9.5% due to pre-transplant immunization. Eighty-three seronegative LT children (aged 7.25 ± 4.40 years; 48.6% male) received two vaccine doses. The seropositive rate increased following the first and second doses and reached to 51.5%, and 92.9%, respectively (p < 0.001), with no serious adverse events reported. Age at vaccination and the interval from transplantation to vaccination were risk factors for non-responsiveness (p < 0.001). The study highlighted inadequate HAV vaccination coverage, leaving most LT children susceptible to infection. HAV vaccine proved highly immunogenic and safe, emphasizing the need for improved vaccination strategies before and after liver transplantation.Trial registration TCTR20220110001.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje